昂利康涨停报57.20元 新获美索巴莫注射液注册证书

Group 1 - The core point of the article is that Anglikon has received approval for its Mesobam injection, which is intended for the treatment of acute skeletal muscle pain, potentially enhancing the company's product pipeline [1] - As of July 31, the stock price of Anglikon reached 57.20 yuan, with a trading volume of 8.22 billion yuan and a turnover rate of 8.08%, resulting in a total market capitalization of 115.39 billion yuan [1] - The approval for the drug includes a registration certificate from the National Medical Products Administration, valid until July 28, 2030, and is considered equivalent to passing the consistency evaluation [1] Group 2 - The sales of the newly approved drug may be influenced by policy and market environment, indicating potential uncertainties in revenue generation [1]